Korean Joint Registry for Alzheimer's Treatment and Diagnostics

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, while enhancing diagnostic methods for Alzheimer's disease. By collecting real-world data from Korean Alzheimer's patients, the study seeks to contribute to more precise treatment approaches and evaluate the impact of these therapies in clinical practice. The study is particularly relevant given the increasing prevalence of dementia in South Korea and the associated socio-economic costs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants must be 19 years of age or older at the time of informed consent.
2. Patients who are undergoing medical evaluation for newly approved Alzheimer's disease medications after 2021, patients who have decided to initiate treatment with these medications in consultation with their physician after 2021, or patients who have already started treatment with newly approved Alzheimer's disease medications after 2021.
3. Patients who have undergone an amyloid PET scan to confirm Alzheimer's disease pathology, or cerebrospinal fluid testing for Aβ42 and ptau181.
4. Clinical diagnosis of Alzheimer's disease, defined as follows:

<!-- -->

1. \[Alzheimer's Disease Dementia (ADD)\] - Must meet the criteria for probable Alzheimer's dementia as defined by the National Institute on Aging and the Alzheimer's Association working groups (NIA-AA).

   * Must exhibit cognitive decline that impairs independent daily living.
2. \[Mild Cognitive Impairment (MCI)\]

   \- Must meet NIA-AA diagnostic criteria for MCI.

   \- The subject or informant must report cognitive decline.

   \- Performance on delayed recall of verbal memory must be more than -1.0 SD below the age- and education-adjusted normative mean, or scores on any one or more tests of executive function, language, visuospatial abilities, or attention must be more than -1.5 SD below the age- and education-adjusted normative mean.

   \- Clinical Dementia Rating scale (CDR) of 0.5.

   \- Maintenance of independent daily living ability.

   \- Not categorized as dementia.
3. \[Cognitively Unimpaired (CU)\]

   \- Delayed recall of verbal memory must be at or above -1.0 SD versus the age- and education-adjusted normative mean, and all executive function, language, visuospatial abilities, and attention tests must be at or above -1.5 SD versus the age- and education-adjusted normative mean.

   \- Maintenance of independent daily living ability.
   * If the subject reports cognitive decline, they will be classified as having Subjective Cognitive Decline (SCD).

     5\. Patients must be ambulatory (use of mobility aids is acceptable). 6. The subject must provide written informed consent to participate in the study. In the case of dementia patients, additional written consent from a guardian is required.

Exclusion Criteria:

1. Presence of significant psychiatric disorders associated with intellectual disability, schizophrenia, major depression, bipolar disorder, delirium, etc.
2. History of substance abuse or alcohol dependence that required treatment within the past five years.
3. A current diagnosis of cancer that has not achieved remission within the past five years. However, localized prostate cancer, cervical carcinoma in situ, non-melanoma skin basal cell carcinoma, or squamous cell carcinoma are excluded.
4. Evidence of severe or unstable physical conditions (e.g., dialysis, severe liver disease).
5. Visual or auditory impairments that prevent the satisfactory assessment of cognitive function.
6. Inability to perform MRI due to the presence of metallic substances in the body.
7. Currently participating in another drug clinical trial.
8. Currently pregnant or breastfeeding.

Where it's running

• Gachon University Gil medical Center
  Incheon, South Korea Recruiting
• Inha University Hospital
  Incheon, South Korea Recruiting
• Ewha Womans University Mokdong Hospital
  Seoul, South Korea Not yet recruiting

Study contacts

• Principal investigator: Geon-ha Kim — Ewha Womans University Mokdong Hospital
• Study coordinator: Geon-ha Kim
• Email: geonha@ewha.ac.kr
• Phone: 82-2-587-7462

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease

  A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT07717567

• Music for Pain and Dementia: Group Drumming for people with early dementia and their caregivers

  This study tests whether group drumming can reduce pain and change brain activity in people with mild dementia or mild cognitive impairment and in their caregivers.

  Recruiting Yale University · New Haven, Connecticut · NCT07602283

• Fast-track screening to determine eligibility for anti-amyloid treatment using digital cognitive tests and blood biomarkers.

  This project will test whether combining self‑administered digital cognitive tests with blood biomarker results can quickly identify patients referred for memory concerns who may qualify for anti‑amyloid disease‑modifying therapy.

  Recruiting MoCA Clinic and Institute · Greenfield Park, Quebec · NCT07041450

• Ultralow-dose amyloid PET with 18F‑Florbetapir or 18F‑Flutemetamol

  This trial will try using a very small amount of an amyloid PET tracer with a high-sensitivity PET scanner to see if clear brain images can be made for people with Alzheimer’s, mild cognitive impairment, other dementias, and healthy volunteers.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07012993

• Using brain stimulation and digital training to improve cognitive function in older adults

  This study is testing whether a combination of brain stimulation and digital training can help improve thinking skills in older adults with Mild Cognitive Impairment and Alzheimer's Disease.

  Recruiting Universidade Federal do Rio de Janeiro · Rio de Janeiro, Rio de Janeiro · NCT06733714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.